To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema

Inclusion Criteria:

1. Signed informed consent must be obtained prior to participation in the study.

2. Patients ≥18 years of age at screening

3. Patients with type 1 or type 2 diabetes mellitus (DM) and Hemoglobin A1c (HbA1c) of ≤10% at screening

4. Medication for the management of diabetes must have been stable within 3 monthsprior to randomization and is expected to remain as stable as medically acceptableduring the course of the study

5. Study Eye Visual impairment due to diabetic macular edema (DME) with:

• Best-corrected visual acuity (BCVA) score between 78 and 23 letters, inclusive,using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA)testing charts at a starting testing distance of 4 meters (approximate Snellenequivalent of 20/32 to 20/320) at screening and baseline

• DME involving the center of the macula, with central subfield retinal thickness (e.g. measured from retinal pigment epithelium (RPE) to the inner limitingmembrane (ILM) inclusively) of ≥320 μm on Spectral domain optical coherencetomography (SD-OCT) at screening.

Exclusion Criteria:

• Active Proliferative diabetic retinopathy (PDR) in the study eye as per investigator

• Concomitant conditions or ocular disorders in the study eye at screening or baselinewhich could, in the opinion of the investigator, prevent response to study treatmentor may confound interpretation of study results, compromise visual acuity or requiremedical or surgical intervention for the duration of the study (e.g. cataract,vitreous hemorrhage, retinal vascular occlusion, retinal detachment, macular hole,or choroidal neovascularization (CNV) of any cause)

• Any active intraocular or periocular infection or active intraocular inflammation (e.g. infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectiousblepharitis, uveitis) in study eye at screening or baseline

• Structural damage of the fovea in the study eye at screening likely to precludeimprovement in visual acuity following the resolution of macular edema (ME),including atrophy of the retinal pigment epithelium, subretinal fibrosis, laserscar(s), epiretinal membrane involving fovea or organized hard exudate plaques

• Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) > 25mmHg on medication or according to investigator's judgment at Screening or Baseline

• Neovascularization of the iris in the study eye at screening or baseline

• Evidence of vitreomacular traction in the study eye at screening or baseline whichin the opinion of the investigator, affects visual acuity

• Previous treatment with any anti-vascular growth factor (VEGF) drug orinvestigational drugs in the study eye